I型干扰素信号在肌病中的作用:小鼠模型研究
该研究在两种小鼠模型中探讨JAK抑制剂治疗肌炎的效果及I型干扰素对肌肉血管的影响;托法替尼降低严重肌炎小鼠的IFN评分并改善生存,但未观察到功能改善,巴瑞替尼无此效果;I型干扰素过表达诱导肌肉炎症和无力。
要点
- 托法替尼降低严重肌炎小鼠的IFN评分并改善生存,巴瑞替尼无此效果。
- 两种JAK抑制剂均未观察到肌肉功能改善。
- I型干扰素过表达诱导肌肉炎症、握力下降和IFN评分升高。
核心结论
- 托法替尼降低IFN特征且该组生存与健康对照无显著差异,而未治疗和巴瑞替尼治疗HT小鼠生存较短。
- 未观察到功能改善。
- I型干扰素信号促进肌肉炎症和无力,是肌肉损伤的关键驱动因素,强化其作为治疗靶点的潜力。
研究设计与样本
- 在MHC I类双转基因(HT)雌性小鼠第21天诱导肌炎,随机分为巴瑞替尼10 mg/kg、托法替尼20 mg/kg、溶剂对照和健康对照四组(每组n=10-11)。
- 为模拟IFNβ过表达,C57BL/6小鼠接受AAV9-tMCK-IFNβ,予溶剂或托法替尼40 mg/kg/天治疗10周(每组n=8-13)。
主要发现
- 托法替尼(而非巴瑞替尼)显著降低严重肌炎小鼠的IFN评分(P < 0.05)。
- 各组生存差异有统计学意义(总体log-rank P < 0.01),未治疗和巴瑞替尼治疗HT小鼠生存短于BL/6对照,而托法替尼治疗小鼠与对照无差异。
- IFNβ过表达诱导肌肉炎症(P < 0.01)、降低握力(P < 0.0001)、增加IFN评分(P < 0.0001)和H2Kb表达(P < 0.0001)。
临床怎么用
- 托法替尼可能通过降低I型干扰素信号改善严重肌炎小鼠生存,但未显示功能获益。
- I型干扰素信号是肌肉炎症和无力的驱动因素,支持其作为治疗靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Dysregulated type I interferon (IFN) signaling contributes to autoimmune myositis pathogenesis. We investigated the therapeutic effects of JAK inhibitors in two mouse models. We also examined how type I IFNs affect muscle vasculature. METHODS: Myositis was induced in major histocompatibility complex class I double transgenic ([TRE-H-2Kb (H mice)/MCK-tTA (T mice)] (HT)) female mice at day 21. Mice were randomized into four groups (n = 10-11/group): baricitinib (10 mg/kg), tofacitinib (20 mg/kg), vehicle, and healthy controls. Outcomes included survival, weight, muscle strength, histopathology, and IFN-stimulated gene expression. To model IFNβ overexpression, C57BL/6 mice received AAV9-triple muscle-specific creatine kinase (tMCK)-IFNβ and were treated with vehicle or tofacitinib (40 mg/kg/day) for 10 weeks (n = 8-13/group). RESULTS: Tofacitinib-but not baricitinib-significantly reduced IFN scores in mice with severe myositis (P < 0.05). Survival differed across groups (overall log-rank P < 0.01), with untreated- and baricitinib-treated HT mice showing shorter survival than BL/6 controls, whereas tofacitinib-treated mice did not differ from controls. IFNβ overexpression induced muscle inflammation (P < 0.01), reduced grip strength (P < 0.0001), and increased the IFN score (P < 0.0001) and H2Kb (P < 0.0001) expression. CONCLUSION: Tofacitinib reduced the IFN signature, and survival in this group did not differ significantly from healthy controls, whereas untreated and baricitinib-treated HT mice showed shorter survival; functional improvement was not observed. Our results also show that type I IFN signaling contributes to muscle inflammation and weakness, making it a key driver of muscle damage and thereby reinforcing its potential as a therapeutic target.
引用
- Spathis R, Narvesen S, Robles Kuriplach D, et al. Investigating the Role of Type I Interferon Signaling on Muscle Disease Using Mouse Models. Arthritis Rheumatol. 2026. PMID: 41707695. doi:10.1002/art.70096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。